McKesson Co. (NYSE:MCK) Shares Bought by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC raised its holdings in McKesson Co. (NYSE:MCK - Free Report) by 11.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,000 shares of the company's stock after buying an additional 2,000 shares during the quarter. McKesson accounts for 4.2% of Sivik Global Healthcare LLC's investment portfolio, making the stock its 6th largest holding. Sivik Global Healthcare LLC's holdings in McKesson were worth $9,888,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Headlands Technologies LLC purchased a new position in McKesson during the first quarter worth about $67,000. Kingsview Wealth Management LLC grew its position in McKesson by 78.9% in the first quarter. Kingsview Wealth Management LLC now owns 1,526 shares of the company's stock worth $819,000 after acquiring an additional 673 shares in the last quarter. HBK Sorce Advisory LLC grew its position in McKesson by 3.0% during the first quarter. HBK Sorce Advisory LLC now owns 1,268 shares of the company's stock valued at $681,000 after acquiring an additional 37 shares during the last quarter. Lord Abbett & CO. LLC boosted its holdings in McKesson by 2.1% during the 1st quarter. Lord Abbett & CO. LLC now owns 83,056 shares of the company's stock valued at $44,589,000 after acquiring an additional 1,689 shares during the period. Finally, Leo Wealth LLC purchased a new position in McKesson during the 1st quarter valued at about $213,000. 85.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

MCK has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft dropped their target price on shares of McKesson from $623.00 to $579.00 and set a "buy" rating on the stock in a report on Wednesday, September 25th. Leerink Partners decreased their price objective on McKesson from $665.00 to $630.00 and set an "outperform" rating on the stock in a research note on Monday, October 7th. JPMorgan Chase & Co. increased their price target on McKesson from $656.00 to $661.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 21st. Citigroup upped their target price on shares of McKesson from $630.00 to $713.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Robert W. Baird raised McKesson from a "neutral" rating to an "outperform" rating and lifted their price objective for the stock from $531.00 to $688.00 in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $631.57.

McKesson Price Performance

MCK stock traded down $14.57 on Thursday, hitting $610.03. 749,297 shares of the company were exchanged, compared to its average volume of 823,953. The stock has a market capitalization of $77.44 billion, a price-to-earnings ratio of 32.35, a price-to-earnings-growth ratio of 1.33 and a beta of 0.44. The business's fifty day moving average is $516.06 and its two-hundred day moving average is $553.41. McKesson Co. has a twelve month low of $431.35 and a twelve month high of $637.51.

McKesson (NYSE:MCK - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share for the quarter, topping the consensus estimate of $6.88 by $0.19. The company had revenue of $93.65 billion during the quarter, compared to the consensus estimate of $89.33 billion. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The company's revenue was up 21.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.23 earnings per share. Equities research analysts expect that McKesson Co. will post 32.81 earnings per share for the current year.

McKesson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 2nd. Shareholders of record on Monday, December 2nd will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Monday, December 2nd. This represents a $2.84 annualized dividend and a yield of 0.47%. McKesson's payout ratio is 14.71%.

Insiders Place Their Bets

In other McKesson news, CEO Brian S. Tyler sold 3,753 shares of the company's stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $561.10, for a total value of $2,105,808.30. Following the transaction, the chief executive officer now directly owns 78,586 shares of the company's stock, valued at $44,094,604.60. This represents a 4.56 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.11% of the stock is owned by corporate insiders.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.